Serum Fibroblast Growth Factor 21 as a Novel Biomarker in Prediction of Coronary Artery Disease Severity
Journal Title: Journal of Advances in Medicine and Medical Research - Year 2016, Vol 18, Issue 9
Abstract
Aims: To evaluate serum FGF-21 concentrations in coronary heart disease patients (CHD) whether or not associated with diabetes and/or hypertension. It also investigated the possible association between serum FGF21 and the coronary angiographic findings in terms of number of coronary vessels affected. Study Design: Cross-sectional observational comparative study. Place and Duration of Study: Coronary angiography unit at the Critical Care Department with Biochemistry Department, Kasr Al Aini Medical Hospitals, from January 2013 to March 2014. Methods: Seventy patients (47 Males and 23 females) were classified after coronary angiography into: Sub-group (A): Coronary Artery Disease patients without DM or hypertension; Sub-group (B): Coronary Artery Disease patients with DM and/or hypertension; Sub-group (C): Patients with normal angiography but suffering from DM and/ or hypertension. Twelve healthy individuals were also included in the present study as a control group. Body Mass Index (BMI) were matched for all groups, systolic and diastolic blood pressure (SBP&DBP) and fasting serum levels of FGF21, glucose, insulin and lipid profile were estimated. Results: A significant increase in the levels of FGF-21 was detected in CHD patients compared to control group (325.8 ± 129.2 Vs 202.2 ± 65.8, P =.002) and significant increase was also found in those with multi-vessel disease affection compared to those with one-vessel affection group (392.1 ± 140.4 Vs 250.7 ± 83.8, P =.007), There was a highly significant positive correlation between serum levels of FGF-21 and each of BMI (r= .7, P > .001), SBP (r= .63, P > .001), and DBP (r= .67, P > .001). ROC curve analysis indicated that the optimum cut off value for plasma FGF 21 level in patients with CHD versus control was 236 pg/ml which gives 68.33% sensitivity and 75% specificity. Conclusion: Circulating FGF21 level could be a biomarker for CHD and may be used for assessment of severity of CHD.
Authors and Affiliations
Mervat M. Khalaf, Salwa Fayez, Taha Azouz
Keywords
Related Articles
- EP ID EP340953
- DOI 10.9734/BJMMR/2016/29581
- Views 60
- Downloads 0
CDKAL1, KCNQ1, and IGF2BP2 are Identified as Type 2 Diabetes Susceptibility Genes in a Regional Chinese Population
Aims: Diabetes has become a major public health problem in China. Recent advances in genetic studies have identified numerous susceptibility loci for type 2 diabetes (T2D). Current models to detect risk of T2D are largel...
Effect of Adhesion Promoter on Bond Strength of Reconditioned Brackets – an In vitro Study
Objectives: To compare the shear bond strength of recycled orthodontic metal brackets using an adhesion booster and conventional primer and using the Adhesive Remnant Index (ARI) score to assess the site of debonding. Ma...
Effects on Fat Distribution by Food Restriction in Zucker Diabetic Fatty Rats
Aim: Zucker diabetic fatty (ZDF) rat is a type 2 diabetic model with hyperphagia, obesity, and the overt fat storage. The present study investigated effects of food restriction for 15 weeks on the fat distribution in ZDF...
Fetal Outcome of Deliveries among Teenagers in Centre Region of Cameroon
Aims: In order to inform public health action, we sought to compare the fetal outcome of adolescent pregnancies with the non-adolescent ones. Study Design: Retrospective cross sectional study. Place and Duration of Stu...
Emotional and Social Disorders among Overweight and Obese Children in Enugu, Nigeria: An Evolving Menace
Background: Obesity results mainly from changes in diet and physical activity and currently being regarded as a global epidemic. It comes at a cost, affecting physical, social and psychological health and having deleteri...